Acute ibogaine injection induces expression of the immediate early genes, egr-1 and c-fos, in mouse brain

Molecular Brain Research

Volumn 74, Issue 1-2, 1999, Pages 237-241

  Ali, Syed F ^a   Thiriet, Nathalie ^b   Zwiller, Jean ^b  

^a Neurochemistry Laboratory   (United States)

^b CENTRE DE NEUROCHIMIE   (France)

Author keywords

C fos; Early gene expression; Egr 1; Ibogaine; Neurotoxicity

Indexed keywords

IBOGAINE; MESSENGER RNA;

ANIMAL MODEL; ANIMAL TISSUE; BRAIN; CAUDATE NUCLEUS; DENTATE GYRUS; FRONTAL CORTEX; GENE EXPRESSION; HIPPOCAMPUS; IMMEDIATE EARLY GENE; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PRIORITY JOURNAL; PUTAMEN; SHORT SURVEY;

EID: 0033392354     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00283-1     Document Type: Article

References (37)

1. Abraham W.C., Mason S.E., Demmer J., Williams J.W., Richardson C.L., Tate W.P., Lawlor P.A., Dragunow M. Correlation between immediate early gene induction and the persistence of long-term potentiation. Neuroscience. 56:1993;717-727.
2. Ali S.F., Newport G.D., Holson R.R., Slikker W. Jr., Bowyer J.F. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res. 658:1994;33-38.
3. S.F. Ali, C.S. Chetty, X.M. Meng, G.D. Newport, W. Slikker, Jr., A single injection of ibogaine produces significant changes in nitric oxide synthase activity and monoamine concentrations in mouse brain, Res. Commun. Subst. Abuse (1999) submitted.
4. Ali S.F., Newport G.D., Slikker W. Jr., Rothman R., Baumann M.H. Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. Brain Res. 737:1996;215-220.
5. M. Baumann, R.B. Rothman, S.F. Ali, Is ibogaine like MK-801? A comparative neurobiological investigation, Drug and Alcohol Depend (1999) accepted for publication.
6. Bhat R.V., Baraban J.M. Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine system. J. Pharmacol. Exp. Ther. 267:1993;496-505.
7. Chen K., Kokat T.G., Carroll S.D.F.I., Rogawski M.A. Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology. 35:1996;423-431.
8. Dilts R.P., Helton T.E., McGinty J.F. Selective induction of Fos and Fra immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields. Synapse. 13:1993;251-263.
9. 1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate early gen and substance P expression in the striatum. Neuroscience. 74:1996;813-823.
10. Ennulate D.J., Babb S.B., Cohen B.M. Persistent reduction of immediate early gene mRNA in rat forebrain following single and multiple doses of cocaine. Mol. Brain Res. 26:1994;106-112.
11. Glick S.D., Rossman K., Steindorf S., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
12. Glick S.D., Rossman K., Rao N.C., Maisonnevue I.M., Carlson J.N. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology. 31:1992;497-500.
13. Glick S.D., Maisonnevue I.M. Mechanisms of anti-addictive action of ibogaine. Ann. N.Y. Acad. Sci. 44:1998;214-226.
14. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6912-6916.
15. Herrera D.G., Robertson H.A. Activation of c-fos in the brain. Pro. Neurobiol. 50:1995;83-107.
16. Humbolt N., Thiriet N., Gobaille S., Aunis D., Zwiller J. The serotonergic system modulates the cocaine-induced expression of the immediate early genes egr-1 and c-fos in rat brain. Ann. N.Y. Acad. Sci. 844:1998;7-20.
17. Karler R., Calder L.D., Chaudry I.A., Turkanis S.A. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci. 45:1989;599-606.
18. Maisonneuve I.M., Keller R.W., Glick S.D. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur. J. Pharmacol. 199:1991;35-42.
19. Maisonneuve I.M., Rossman K., Keller R.W., Glick S.D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 575:1992;69-73.
20. Mash D.C., Staley J.K., Bauamnn M.H., Rothman R.B., Hearn W.L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates. Life Sci. 57:1995;45-50.
21. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
22. Mello C.V., Vicario D.S., Clayton D.F. Song presentation induces gene expression in the songbird forebrain. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6818-6822.
23. Miller D.B., O'Callagahan J.P. Environment-, drug-, and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57Bl/6J mouse. J. Pharmacol. Exp. Ther. 270:1994;752-768.
24. Moratalla R., Robertson H.A., Graybiel A.M. Dynamic regulation of NGF-1A (zif268, egr-1) gene expression in the striatum. J. Neurosci. 12:1992;2609-2622.
25. Popik P., Layer R.T., Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a anti-addictive drug. Pharmacol. Rev. 47:1995;235-253.
26. 3H ]MK-801 binding to the NMDA receptor complex Psychopharmacology. 114:1994;672-674.
27. Scallet A.C., Ye X., Rountree R., Nony P., Ali S.F. Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum. Ann. N.Y. Acad. Sci. 844:1998;217-226.
28. Scallet A.C., Ye X., Ali S.F. NOS and fos in rat and mouse brain regions. Ann. N.Y. Acad. Sci. 844:1998;227-238.
29. Sershen H., Hashim A., Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol. Biochem. Behav. 47:1994;13-19.
30. Torres G., Rivier C. Induction of c-fos in rat brain by acute cocaine and fenfluramine exposure. A comparative study. Brain Res. 647:1994;1-9.
31. Sweetnam P.M., Lancaster J., Snowman A., Collins J., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggest multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology. 118:1995;369-376.
32. Thiriet N., Humblot N., Burgun C., Aunis D., Zwiller J. Cocaine and fluoxitine induce the expression of the hVH-5 gene encoding MAP kinase phosphatase. Mol. Brain Res. 62:1998;150-157.
33. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist, MK-801. Science. 251:1991;85-87.
34. Worley P.F., Bhat R.V., Baraban J.M., Erickson C.A., McNaughton B.C., Barnes A. Threshold for synaptic activation of transcription factors in hippocampus: correlation with long-term enhancement. J. Neurosci. 13:1993;4776-4786.
35. Wu P.H., Michic S.J., Liu J.F., Dzung Le A., Kalant H. Blockade of chronic tolerance to ethanol by the NMDA antagonist, (+)MK-801. Eur. J. Pharmacol. 231:1993;157-164.
36. 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1291-1295.
37. Yu X., Imam S.Z., Newport G.D., Slikker W. Jr., Ali S.F. Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice. Brain Res. 823:1999;213-216.